))
CAR T-Cell Pioneer Takes Aim at Where No Campus Has Gone Before
Manage episode 362863545 series 2773261
Content provided by University of Colorado Anschutz Medical Campus. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by University of Colorado Anschutz Medical Campus or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode of the CU Anschutz 360 podcast, Terry Fry, MD, the inaugural executive director and Charles C. Gates Endowed Chair of the Gates Institute, explains how the institute is heading toward new frontiers of targeted cell and gene therapies for cancers and other rare diseases. Fry talks about the latest advances in chimeric antigen receptor (CAR T) cell therapies, which he helped pioneer at the National Institutes of Health. He talks about how the Gates Institute, which connects and centralizes campus resources into a seamless translational pathway, offers an incredible opportunity to help patients facing serious health issues. Thomas Flaig, MD, CU Anschutz vice chancellor for research, co-hosts the discussion.
51 episodes
Share
